| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | -20.12% | -40.24% | -393.91% | — | — | — | — | — |
| EBITDA Margin | — | -19.79% | -39.90% | -393.16% | — | — | — | — | — |
| Net Margin | — | -19.63% | -36.96% | -396.14% | — | — | — | — | — |
| Current Ratio | 10.58 | 3.93 | 1.79 | 2.40 | 9.35 | 11.76 | 14.28 | 33.09 | 12.57 |
| Quick Ratio | 10.58 | 3.93 | 1.79 | 2.40 | 9.35 | 11.76 | 14.28 | 33.09 | 12.57 |
| Debt / Equity | — | — | — | 0.28 | 0.15 | 0.14 | 0.23 | — | — |
| ROE | -78.32% | -42.32% | -59.08% | -195.44% | -58.72% | -42.68% | -61.17% | -20.41% | — |
| ROA | -70.24% | -31.51% | -26.39% | -79.61% | -45.73% | -34.90% | -46.09% | -19.73% | — |
| Asset Turnover | — | 1.61 | 0.71 | 0.20 | — | — | — | — | — |
| Book Value / Share | 0.50 | 0.54 | 0.65 | 0.95 | 2.31 | — | — | — | — |
Equillium, Inc. is a clinical-stage biotechnology company headquartered in La Jolla, California, focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with significant unmet medical needs. The company's lead product candidate is Itolizumab (EQ001), a first-in-class anti-CD6 immune-modifying monoclonal antibody currently in phase 3 clinical trials for acute graft-versus-host disease, with additional development in systemic lupus erythematosus and ulcerative colitis. The company also develops EQ101, a selective tri-specific inhibitor targeting multiple interleukin pathways for cutaneous T cell lymphoma treatment, and EQ504, an aryl hydrocarbon receptor modulator being advanced for ulcerative colitis. Equillium serves multiple medical specialties including gastroenterology, dermatology, hematology, transplant science, rheumatology, pulmonology, and oncology. The company is advancing its pipeline through strategic financing initiatives and partnerships while maintaining focus on improving capital efficiency and clinical development.